Shares of Aurobindo were locked in a 20 per cent upper circuit at Rs 602.25 on 19 February.

Analysts expect the acquisition to be funded through a bridge loan, with quick de-leveraging by FY22 through internal accruals.

The lack of disclosures around non-related party transactions to the tune of Rs 2,200 crore has become a sore spot for investors, who are q...

Sun Pharma- India's largest drug maker - is vying for its share in the US$9 billion market through a drug, Ilumya, that treats moderate-to-...

While the market opportunities to sell brands appear optimistic, that road is less treaded by Indian companies and obvious challenges can l...

“Both US presidential candidates have argued in favour of allowing the US government’s Medicare programme, which accounts for over 20% of t...

Kotak Securities said a Democrat sweep across houses could pose even greater pricing challenges for the industry, and for both brand name a...

Dr. Reddy’s informed stock exchanges that 3 of its key sites received warning letters from US FDA and will need to submit correction plans ...